Tamsulosin + Tadalafil capsules are a ground-breaking treatment introduced by Akums Drugs and Pharmaceuticals. These capsules treat both an enlarged prostate and erectile dysfunction, which is a significant accomplishment for the company.

Akums is proud to be the first Contract Development and Manufacturing Organization (CDMO) to receive Drug Controller General of India (DCGI) approval for the Tamsulosin 0.4/0.4mg + Tadalafil 2.5/5mg formulation.

Tamsulosin, an alpha1A-adrenergic receptor antagonist, works on the smooth muscle receptors of the prostate and urethra to improve urine flow in people who have an enlarged prostate.

Tadalafil inhibits PDE5, found in vascular smooth muscle cells of the corpus cavernosum, allowing for cGMP accumulation and vascular smooth muscle relaxation, facilitating the achievement of an erection upon sexual stimulation.

This specialized Tamsulosin + Tadalafil capsule, containing Tamsulosin Hydrochloride IP and Tadalafil IP, is designed for urology, providing relief for BPH and Erectile Dysfunction, enhancing Total, Voiding, and Storage IPSS scores, and potentially improving LUTS relief.

Sanjeev Jain, Jt MD, Akums Drugs & Pharmaceuticals, said, “The Tamsulosin + Tadalafil Capsule demonstrates Akums’ commitment to advancing healthcare for patients with benign prostatic hyperplasia and erectile dysfunction. This innovative therapy offers convenience and elevates patient outcomes.”

Sandeep Jain, Jt MD, Akums Drugs & Pharmaceuticals, said,

“Our dedicated team’s efforts have led to a product while meeting rigorous regulatory standard, aiming to enhance patients’ quality of life. This capsule reflects Akums’ dedication to innovation and healthcare standards.”